Tucked into the Kremlin statement about a proposed Ukraine cease-fire agreement were several very specific conditions. For ...

Even as it bolstered itself against a takeover, the company's board said it would hear out the billionaire investor's proposal.

Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...

Drug development company Acelyrin Inc. recently saw a modest increase in its stock price after announcing the adoption of a ...

Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.

The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will ...

Target companies can use certain defenses, such as a poison pill or a golden parachute, to ward off hostile takeovers. Investopedia / Matthew Collins A hostile takeover allows the new majority ...